THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.18] ID: TIP-MED-000454 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Etizolam, Chlordiazepoxide & Clobazam

Active Ingredient / Scientific Identity: Etizolam, Chlordiazepoxide & Clobazam • Class: Thienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazepine Anxiolytics/Anticonvulsant (Schedule H1 / H | NLEM 2022 [Clobazam])

⚖️ Compare Profile
Generic / Entity NameEtizolam, Chlordiazepoxide & Clobazam ([11.18])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassThienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazepine Anxiolytics/Anticonvu
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule H1 (Rx — 3-Year Register Retention & Red-Border Warning)
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 (Rx — 3-Year Register Retention & Red-Bo🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Etizolam, Chlordiazepoxide & Clobazam (TIP-MED-000454, Reference Code [11.18]) is classified under Neurology Medicines as a Thienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazepine Anxiolytics/Anticonvulsant (Schedule H1 / H | NLEM 2022 [Clobazam]). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 (Rx — 3-Year Register Retention & Red-Border Warning).

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Etizolam: Etilaam (Intas), Etizola (Macleods), Macfresh; FDCs with Escitalopram or Propranolol. Chlordiazepoxide: Librium (Abbott), Equilibrium; | Strengths: Etizolam Tablets / MD: 0.25 mg, 0.5 mg, 1 mg. Chlordiazepoxide Tablets: 10 mg, 25 mg. Clobazam Tablets: 5 mg, 10 mg, 20 mg
Representative Indian Formulations (for identification only): Etizolam: Etilaam (Intas), Etizola (Macleods), Macfresh; FDCs with Escitalopram or Propranolol. Chlordiazepoxide: Librium (Abbott), Equilibrium; | Strengths: Etizolam Tablets / MD: 0.25 mg, 0.5 mg, 1 mg. Chlordiazepoxide Tablets: 10 mg, 25 mg. Clobazam Tablets: 5 mg, 10 mg, 20 mg
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Thienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazepine Anxiolytics/Anticonvulsant (Schedule H1 / H | NLEM 2022 [Clobazam])): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Etizolam: Short-term management (<=2–4 weeks) of acute anxiety and panic attacks.

4. Therapeutic Indications & Evidence-Supported Uses

  • Etizolam: Short-term management (<=2–4 weeks) of acute anxiety and panic attacks
  • Chlordiazepoxide: First-line long-acting benzodiazepine for Acute Alcohol Withdrawal Syndrome / Delirium Tremens prophylaxis (CIWA-Ar symptom-triggered or fixed 5–7 day taper — active metabolites desmethyldiazepam/oxazepam provide smooth

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Etizolam: 0.25–0.5 mg PO BD or HS (Max 1.5–2 mg/day for <=2–4 weeks). Chlordiazepoxide (Alcohol Withdrawal): Day 1: 25–50 mg PO q6h (+ Thiamine 100–500 mg IV/PO!), then taper by 20–25% daily over 5–7 days and STOP. Clobazam (Epilepsy): Start 5–10 mg PO at bedtime, titrate to 10–20 mg BD (Max 40–60 mg/day) (Duration: Etizolam: <=2–4 weeks; Chlordiazepoxide: 5–7 day alcohol detox taper; Clobazam: Chronic epilepsy adjunct (never stop Clobazam abruptly in epilepsy — precipitates status epilepticus!))

Administration & Meal Timing: Oral (PO) | Food & Meal Timing: May be taken with or without food | Best Time of Day: Bedtime or BD (q6h tapering for Chlordiazepoxide in alcohol detox)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal: Start at lowest dose in severe CKD. Hepatic: AVOID Chlordiazepoxide in Child–Pugh B/C cirrhosis (switch to Lorazepam!); reduce Clobazam & Etizolam by 50%
Elimination & Renal Adjustment:
Renal: Start at lowest dose in severe CKD. Hepatic: AVOID Chlordiazepoxide in Child–Pugh B/C cirrhosis (switch to Lorazepam!); reduce Clobazam & Etizolam by 50%
Hepatic Impairment Considerations:
Renal: Start at lowest dose in severe CKD. Hepatic: AVOID Chlordiazepoxide in Child–Pugh B/C cirrhosis (switch to Lorazepam!); reduce Clobazam & Etizolam by 50%

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CONTRAINDICATED in myasthenia gravis, severe respiratory insufficiency, severe sleep apnoea, and acute narrow-angle glaucoma
  • Note: In Cirrhosis / Alcoholic Liver Disease with Jaundice or Ascites, Chlordiazepoxide (half-life >100h via CYP450) accumulates and precipitates hepatic coma — use **Lorazepam** (glucuronidated, non-CYP) for alcoh

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Drowsiness, fatigue, ataxia, dizziness, anterograde amnesia, dependence and rebound insomnia/anxiety on abrupt withdrawal
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Active metabolite of Clobazam (N-desmethylclobazam) is cleared by CYP2C19: Potent CYP2C19 inhibitors (Fluconazole, Fluvoxamine, Omeprazole, Esomeprazole, Cannabidiol) increase N-desmethylclobazam levels 3–5-fold -> profound sedation & ataxia! CYP3A4 inhibitors (Itraconazole, Clarithromycin) increase

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • COUNTER CHECKS: (1) Never stop Frisium (Clobazam) suddenly in epilepsy (triggers continuous seizures)
  • (2) For Etilaam (Etizolam), use only for 2–4 weeks while long-term SSRI takes effect, then taper off slowly

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Etizolam Tablets / MD: 0.25 mg, 0.5 mg, 1 mg. Chlordiazepoxide Tablets: 10 mg, 25 mg. Clobazam Tablets: 5 mg, 10 mg, 20 mg). Missed-Dose Rule: In epilepsy (Frisium), take missed dose as soon as remembered; in anxiety, do not double dose

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.